This ECDC protocol for a focused after-action review (AAR) on evidence-based decision-making (EBDM) for selected COVID-19 response measures uses the standard AAR/IAR approach but focuses on a single category or function – EBDM – as opposed to a whole range of activities.
This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.
The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, focusing in particular on the experience in EU/EEA countries since the beginning of the pandemic. This document also addresses transmission to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing, and the effectiveness and impacts of school closures.
This indicator framework, developed by ECDC together with WHO/Europe, is intended for use by relevant national health authorities, public health and related institutions and their partners involved in the planning, implementation, monitoring and evaluation of contact tracing activities.
This study provides insights for national public health authorities into the factors behind the spread of vaccine misinformation online and the options and capacities needed for responding to it.
This report presents evidence on the impact of COVID-19 on migrant populations in EU/EEA countries; risk factors for increased COVID-19 exposure in migrant populations; and considerations for ensuring equitable access to the COVID-19 vaccine for migrant populations.
This technical report provides a set of interim public health considerations to support EU/EEA public health authorities taking decisions on the administration of COVID-19 vaccines to adolescents (12- to 18-year-olds).
This document offers practical guidance for EU/EEA Member States on implementing genomic SARS-CoV-2 surveillance. It also includes advice on how to estimate the number of sequenced samples needed to achieve various objectives, including the early detection of novel variants.
Several SARS-CoV-2 variants have been identified. Some of these variants have mutations that (alone or in combination) may provide the virus with a selective advantage, such as increased transmissibility or the ability to evade the host immune response, or cause possible changes in pathogenicity, thus increasing disease severity.